NSE: ABBOTINDIA | BSE: 500488

Expensive Performer

Download real time

34295.00 -125.00 (-0.36%)

35.42% Gain from 52W Low

2,617 NSE+BSE Volume

NSE 14 Jul, 2025 3:31 PM (IST)

72,874.5

Market Cap

High in industry

0.5

Beta 1Year

Very Low volatility

Dividend

Abbott India Ltd. has an upcoming dividend of ₹475.00 per share due on 25 Jul 2025 See details

Abbott India Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for ABBOTINDIA, BSE:500488 Abbott India Ltd.

Abbott India Ltd.

12 May 2024

34295.00

-0.36%

Sailing through turbulence

Buy: Abbott India Ltd.

Target

ICICI Securities Limited

Abbott India’s (Abbott) Q4FY24 revenue growth of 7% was slightly below expectation of 9%; however, its 9.4% growth in FY24 was still ahead of industry growth of ~8%. Sequential drop of 197/407bps in gross/EBITDA margin was on account of higher third-party sourcing and higher overhead cost.

BOB Capital Markets Ltd. increased Buy price target of Abbott India Ltd. to 40128.0 on 04 Jul, 2025.

Abbott India Ltd.

10 May 2024

34295.00

-0.36%

Result Update:Abbott India

Buy: Abbott India Ltd.

Target

Axis Direct

We have BUY on the stock.

BOB Capital Markets Ltd. increased Buy price target of Abbott India Ltd. to 40128.0 on 04 Jul, 2025.

Abbott India Ltd.

09 May 2024

34295.00

-0.36%

Healthy earnings; growth momentum to continue

Buy: Abbott India Ltd.

Target

Sharekhan

? Abbott reported healthy earnings an annual basis but earnings lagged our estimates where sales grew by 7%
y-o-y to Rs 1438 crore (1.3% below our estimates), EBITDA grew by 17.7% y-o-y to Rs 329 crore (13% below our estimates) and PAT grew by 29% y-o-y to Rs 287 crore (4% below our estimates).

Abbott India Ltd. has gained 20.10% in the last 6 Months

Abbott India Ltd.

02 Feb 2024

34295.00

-0.36%

Result Update:Abbott India

Buy: Abbott India Ltd.

Recommendation Target

Axis Direct

Abbott India is growing 1.6 to 1.8 times faster than IPM, based on high brand recognition and an excellent product portfolio.Recommendation: BUY.

Abbott India Ltd. has an average target of 34719.50 from 4 brokers.

Abbott India Ltd.

13 Nov 2023

34295.00

-0.36%

Result Update:Abbott India

Hold: Abbott India Ltd.

Axis Direct

Abbott India is growing 1.6 to 1.8 times faster than IPM, based on high brand recognition and an excellent product portfolio.. We have a Hold on the stock.

Abbott India Ltd. has gained 20.10% in the last 6 Months

Abbott India Ltd.

11 Aug 2023

34295.00

-0.36%

Result Update:Abbott India

Hold: Abbott India Ltd.

Target

Axis Direct

Company Outlook & Guidance: Abbott India is growing 1.6 to 1.8 times faster than IPM, based on high brand recognition and an excellent product portfolio. Recommendation: HOLD

Abbott India Ltd. is trading above all available SMAs

Abbott India Ltd.

10 Aug 2023

34295.00

-0.36%

Growth pace accelerating

Buy: Abbott India Ltd.

Target

ICICI Securities Limited

Abbott India (Abbott) continues to fare better than its MNC peers who are struggling for growth in line with the market rate for last couple of quarters. In Q1FY24, Abbott grew 13.4% ahead of the market growth of 9% despite mandated price cut on NLEM products (26% of core portfolio sales).

Abbott India Ltd. has gained 20.10% in the last 6 Months

Abbott India Ltd.

22 May 2023

34295.00

-0.36%

Rising above the challenges

Buy: Abbott India Ltd.

Recommendation Target

ICICI Securities Limited

Abbott India (Abbott) has been a consistent performer. Its strong set of brands has helped it report a YoY revenue growth for the last 22 quarters and heckled challenges like competition in existing brands, mandated price cuts. Despite being an MNC, Abbott has served to the local needs better by launching line extensions and entering new therapies.

BOB Capital Markets Ltd. increased Buy price target of Abbott India Ltd. to 40128.0 on 04 Jul, 2025.

Abbott India Ltd.

22 May 2023

34295.00

-0.36%

Result Update:Abbott India

Hold: Abbott India Ltd.

Recommendation Target

Axis Direct

Company Outlook & Guidance: In last 2 quarters, company' growth has moderated and gross margins also has decresed due to higher proportion from Antidiabetic segment.Current Valuation: PE40x for FY25 earnings (Earlier Valuation:PE40x)